Downside risk in CNOOC’s capex; pessimistic expectations priced in
Profit may continue to beat in next few quarters
3Q rev/np +3%/59%; cost cut was key to profit growth
Lead the way as the renewable frontrunner
Peptide business becoming a new growth driver